David Cunningham

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Hawkes Eliza; Chau Ian; Ilson David H; Cunningham David
Upper gastrointestinal malignancies: a new era in clinical colorectal cancer.
Okines A; Puerto O Del; Cunningham D; Chau I; Van Cutsem E; Saltz L; Cassidy J
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
Okines Alicia; Cunningham David
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of David Cunningham (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Hawkes Eliza; Chau Ian; Ilson David H; Cunningham David
Upper gastrointestinal malignancies: a new era in clinical colorectal cancer.
Clinical colorectal cancer 2009;8(4):185-9.
2009: Okines A; Puerto O Del; Cunningham D; Chau I; Van Cutsem E; Saltz L; Cassidy J
Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial.
British journal of cancer 2009;101(7):1033-8.
2009: Okines Alicia; Cunningham David
Current perspective: bevacizumab in colorectal cancer--a time for reappraisal?
European journal of cancer (Oxford, England : 1990) 2009;45(14):2452-61.
2009: Starling Naureen; Rao Sheela; Cunningham David; Iveson Timothy; Nicolson Marianne; Coxon Fareeda; Middleton Gary; Daniel Francis; Oates Jacqueline; Norman Andrew Richard
Thromboembolism in patients with advanced gastroesophageal cancer treated with anthracycline, platinum, and fluoropyrimidine combination chemotherapy: a report from the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):3786-93.
2009: Leary Alexandra; Assersohn L; Cunningham D; Norman A R; Chong G; Brown G; Ross P J; Costello C; Higgins L; Oates J
A phase II trial evaluating capecitabine and irinotecan as second line treatment in patients with oesophago-gastric cancer who have progressed on, or within 3 months of platinum-based chemotherapy.
Cancer chemotherapy and pharmacology 2009;64(3):455-62.
2009: Chau I; Cunningham D
Treatment in advanced colorectal cancer: what, when and how?
British journal of cancer 2009;100(11):1704-19.
2009: Starling N; Okines A; Cunningham D; Allum W; Wotherspoon A; Benson M; Thompson J; Thomas J; Brown G; Riddell A; Stavridi F; Ashley S; Oates J; Chau I
A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma.
British journal of cancer 2009;100(11):1725-30.
2009: Jackson C; Cunningham D; Oliveira J;
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20 Suppl 4():34-6.
2009: Chau I; Norman A R; Cunningham D; Oates J; Hawkins R; Iveson T; Nicolson M; Harper P; Seymour M; Hickish T
The impact of primary tumour origins in patients with advanced oesophageal, oesophago-gastric junction and gastric adenocarcinoma--individual patient data from 1775 patients in four randomised controlled trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(5):885-91.
2009: Yau Thomas; Watkins David; Cunningham David; Barbachano Yolanda; Chau Ian; Chong Geoffrey
Longitudinal assessment of quality of life in rectal cancer patients with or without stomas following primary resection.
Diseases of the colon and rectum 2009;52(4):669-77.
2009: Cunningham D; Sirohi B; Pluzanska A; Utracka-Hutka B; Zaluski J; Glynne-Jones R; Koralewski P; Bridgewater J; Mainwaring P; Wasan H; Wang J-Y; Szczylik C; Clingan P; Chan R T T; Tabah-Fisch I; Cassidy J
Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2009;20(2):244-50.
2009: Hewish Madeleine; Chau Ian; Cunningham David
Insulin-like growth factor 1 receptor targeted therapeutics: novel compounds and novel treatment strategies for cancer medicine.
Recent patents on anti-cancer drug discovery 2009;4(1):54-72.
2008: Rao S; Starling N; Cunningham D; Benson M; Wotherspoon A; Lüpfert C; Kurek R; Oates J; Baselga J; Hill A
Phase I study of epirubicin, cisplatin and capecitabine plus matuzumab in previously untreated patients with advanced oesophagogastric cancer.
British journal of cancer 2008;99(6):868-74.
2008: Starling N; Cunningham D
Survival from cancer of the pancreas in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S24-5.
2008: Rao S; Cunningham D
Survival from cancer of the stomach in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S19-20.
2008: Rao S; Cunningham D
Survival from cancer of the oesophagus in England and Wales up to 2001.
British journal of cancer 2008;99 Suppl 1():S14-5.
2008: Okines Alicia; Chau Ian; Cunningham David
Capecitabine in gastric cancer.
Drugs of today (Barcelona, Spain : 1998) 2008;44(8):629-40.
2008: Cunningham D; Oliveira J;
Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2008;19 Suppl 2():ii23-4.
2008: Jackson Christopher; Cunningham David
Where to position monoclonal antibodies in first-line treatment of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2008;44(5):652-62.
2008: Bianchini Diletta; Jayanth Akali; Chua Yu Jo; Cunningham David
Epidermal growth factor receptor inhibitor-related skin toxicity: mechanisms, treatment, and its potential role as a predictive marker.
Clinical colorectal cancer 2008;7(1):33-43.
2008: Cunningham David; Starling Naureen; Rao Sheela; Iveson Timothy; Nicolson Marianne; Coxon Fareeda; Middleton Gary; Daniel Francis; Oates Jacqueline; Norman Andrew Richard;
Capecitabine and oxaliplatin for advanced esophagogastric cancer.
The New England journal of medicine 2008;358(1):36-46.
2007: Jackson Christopher; Cunningham David
A retrospective on the inhibition of epidermal growth factor receptor as a therapeutic strategy for patients with relapsed metastatic colorectal cancer: impact on treatment of today's patients.
Clinical colorectal cancer 2007;7 Suppl 1():S8-15.
2007: Cunningham David; Starling Naureen
Adjuvant chemotherapy of colorectal cancer.
Lancet 2007;370(9604):1980-1.
2007: Cunningham David; Chua Yu Jo
East meets west in the treatment of gastric cancer.
The New England journal of medicine 2007;357(18):1863-5.
2007: Watkins David; Cunningham David
The role of epidermal growth factor receptor-targeted antibody therapy in previously treated colorectal cancer.
Clinical colorectal cancer 2007;6 Suppl 2():S47-52.
2007: Chua Yu Jo; Cunningham David
The UK NCRI MAGIC trial of perioperative chemotherapy in resectable gastric cancer: implications for clinical practice.
Annals of surgical oncology 2007;14(10):2687-90.
2007: Arkenau Hendrik-Tobias; Chua Yu Jo; Cunningham David
Current treatment strategies in elderly patients with metastatic colorectal cancer.
Clinical colorectal cancer 2007;6(7):508-15.
2007: Arkenau Hendrik-Tobias; Gordon Claire; Murphy Felicity; Cunningham David
Paraneoplastic syndrome: subacute cerebellar degeneration in Hodgkin's disease.
Leukemia & lymphoma 2007;48(4):819-22.
2007: Sirohi Bhawna; Cunningham David; Norman Andy; Last Kim; Chau Ian; Horwich Alan; Oates Jacqui; Chong Geoffrey; Wotherspoon Andrew
Gemcitabine, cisplatin and methylprednisolone (GEM-P) with or without Rituximab in relapsed and refractory patients with diffuse large B cell lymphoma (DLBCL).
Hematology (Amsterdam, Netherlands) 2007;12(2):149-53.
2007: Formica V; Wotherspoon A; Cunningham D; Norman A R; Sirohi B; Oates J; Chong G
The prognostic role of WHO classification, urinary 5-hydroxyindoleacetic acid and liver function tests in metastatic neuroendocrine carcinomas of the gastroenteropancreatic tract.
British journal of cancer 2007;96(8):1178-82.
2007: Chau I; Cunningham D; Hickish T; Massey A; Higgins L; Osborne R; Botwood N; Swaisland A
Gefitinib and irinotecan in patients with fluoropyrimidine-refractory, irinotecan-naive advanced colorectal cancer: a phase I-II study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(4):730-7.
2007: Arkenau Hendrik-Tobias; Gordon Claire; Cunningham David; Norman Andy; Wotherspoon Andrew; Chau Ian
Mucosa associated lymphoid tissue lymphoma of the lung: the Royal Marsden Hospital experience.
Leukemia & lymphoma 2007;48(3):547-50.
2007: Arkenau H-T; Chong G; Cunningham D; Watkins D; Agarwal R; Sirohi B; Trumper M; Norman A; Wotherspoon A; Horwich A
The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2007;18(3):541-5.
2007: Arkenau Hendrik-Tobias; Chong Geoff; Cunningham David; Watkins David; Sirohi Bhawna; Chau Ian; Wotherspoon Andrew; Norman Andy; Horwich Alan; Matutes Estella
Gemcitabine, cisplatin and methylprednisolone for the treatment of patients with peripheral T-cell lymphoma: the Royal Marsden Hospital experience.
Haematologica 2007;92(2):271-2.
2007: Starling N; Tilden D; White J; Cunningham D
Cost-effectiveness analysis of cetuximab/irinotecan vs active/best supportive care for the treatment of metastatic colorectal cancer patients who have failed previous chemotherapy treatment.
British journal of cancer 2007;96(2):206-12.
2007: Jackson Christopher; Starling Naureen; Chua Yu Jo; Cunningham David
Pharmacotherapy for oesophagogastric cancer.
Drugs 2007;67(17):2539-56.
2006: Chua Yu Jo; Cunningham David
Panitumumab.
Drugs of today (Barcelona, Spain : 1998) 2006;42(11):711-9.
2006: Riddell Angela M; Hillier Julia; Brown Gina; King D Michael; Wotherspoon Andrew C; Thompson Jeremy N; Cunningham David; Allum William H
Potential of surface-coil MRI for staging of esophageal cancer.
AJR. American journal of roentgenology 2006;187(5):1280-7.
2006: Starling N; Cunningham D
The role of systemic therapy for localised gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17 Suppl 10():x115-21.
2006: Chau I; Cunningham D
Adjuvant therapy in colon cancer--what, when and how?
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(9):1347-59.
2006: Cunningham David; Allum William H; Stenning Sally P; Thompson Jeremy N; Van de Velde Cornelis J H; Nicolson Marianne; Scarffe J Howard; Lofts Fiona J; Falk Stephen J; Iveson Timothy J; Smith David B; Langley Ruth E; Verma Monica; Weeden Simon; Chua Yu Jo; MAGIC Trial Participants
Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.
The New England journal of medicine 2006;355(1):11-20.
2006: Trumper M; Ross P J; Cunningham D; Norman A R; Hawkins R; Seymour M; Harper P; Iveson T; Nicolson M; Hickish T
Efficacy and tolerability of chemotherapy in elderly patients with advanced oesophago-gastric cancer: A pooled analysis of three clinical trials.
European journal of cancer (Oxford, England : 1990) 2006;42(7):827-34.
2006: Chau I; Cunningham D; Russell C; Norman A R; Kurzawinski T; Harper P; Harrison P; Middleton G; Daniels F; Hickish T; Prendeville J; Ross P J; Theis B; Hull R; Walker M; Shankley N; Kalindjian B; Murray G; Gillbanks A; Black J
Gastrazole (JB95008), a novel CCK2/gastrin receptor antagonist, in the treatment of advanced pancreatic cancer: results from two randomised controlled trials.
British journal of cancer 2006;94(8):1107-15.
2006: Chua Yu Jo; Cunningham David
Chemotherapy for advanced pancreatic cancer.
Best practice & research. Clinical gastroenterology 2006;20(2):327-48.
2006: Chua Yu Jo; Cunningham David
Neoadjuvant treatment of unresectable liver metastases from colorectal cancer.
Clinical colorectal cancer 2006;5(6):405-12.
2006: Burton C; Linch D; Hoskin P; Milligan D; Dyer M J S; Hancock B; Mouncey P; Smith P; Qian W; MacLennan K; Jack A; Webb A; Cunningham D
A phase III trial comparing CHOP to PMitCEBO with or without G-CSF in patients aged 60 plus with aggressive non-Hodgkin's lymphoma.
British journal of cancer 2006;94(6):806-13.
2006: Dickinson Michael; Wotherspoon Andrew; Cunningham David
Sub-clinical dissemination of follicular lymphoma in normal sized lymph nodes may not be detected by radiologic staging: a case of disseminated follicular lymphoma detected in nodal clearance as part of therapy for cutaneous melanoma.
Leukemia & lymphoma 2006;47(3):553-6.
2006: Chong G; Bhatnagar A; Cunningham D; Cosgriff T M; Harper P G; Steward W; Bridgewater J; Moore M; Cassidy J; Coleman R; Coxon F; Redfern C H; Jones J J; Hawkins R; Northfelt D; Sreedharan S; Valone F; Carmichael J
Phase III trial of 5-fluorouracil and leucovorin plus either 3H1 anti-idiotype monoclonal antibody or placebo in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2006;17(3):437-42.
2006: Chau Ian; Brown Gina; Cunningham David; Tait Diana; Wotherspoon Andrew; Norman Andrew R; Tebbutt Niall; Hill Mark; Ross Paul J; Massey Alison; Oates Jacqueline
Neoadjuvant capecitabine and oxaliplatin followed by synchronous chemoradiation and total mesorectal excision in magnetic resonance imaging-defined poor-risk rectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(4):668-74.
2005: Chua Yu Jo; Cunningham David
Recent data with anti-epidermal growth factor receptor antibodies and irinotecan in colon cancer.
Clinical colorectal cancer 2005;5 Suppl 2():S81-8.
2005: Maisey N R; Norman A R; Hill A; Massey A; Oates J; Cunningham D
CA19-9 as a prognostic factor in inoperable pancreatic cancer: the implication for clinical trials.
British journal of cancer 2005;93(7):740-3.
2005: Chong G; Dickson J L B; Cunningham D; Norman A R; Rao S; Hill M E; Price T J; Oates J; Tebbutt N
Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan.
British journal of cancer 2005;93(5):510-4.
2005: Burton C; Smith P; Vaughan-Hudson G; Qian W; Hoskin P; Cunningham D; Hancock B; Linch D
Comparison of CHOP versus CIOP in good prognosis younger patients with histologically aggressive non-Hodgkin lymphoma.
British journal of haematology 2005;130(4):536-41.
2005: Negri F V; Wotherspoon A; Cunningham D; Norman A R; Chong G; Ross P J
Mucinous histology predicts for reduced fluorouracil responsiveness and survival in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(8):1305-10.
2005: Chau Ian; Norman Andrew R; Cunningham David; Iveson Tim; Hill Mark; Hickish Tamas; Lofts Fiona; Jodrell Duncan; Webb Andrew; Tait Diana; Ross Paul J; Shellito Pat; Oates Jacqueline R
Longitudinal quality of life and quality adjusted survival in a randomised controlled trial comparing six months of bolus fluorouracil/leucovorin vs. twelve weeks of protracted venous infusion fluorouracil as adjuvant chemotherapy for colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2005;41(11):1551-9.
2005: Chua Yu Jo; Cunningham David
Adjuvant treatment for resectable pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(20):4532-7.
2005: Ng Matthew; Cunningham David; Norman Andrew R
The frequency and pattern of cardiotoxicity observed with capecitabine used in conjunction with oxaliplatin in patients treated for advanced colorectal cancer (CRC).
European journal of cancer (Oxford, England : 1990) 2005;41(11):1542-6.
2005: Sumpter K; Harper-Wynne C; Cunningham D; Rao S; Tebbutt N; Norman A R; Ward C; Iveson T; Nicolson M; Hickish T; Hill M; Oates J
Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF.
British journal of cancer 2005;92(11):1976-83.
2005: Rao S; Cunningham D; Hawkins R E; Hill M E; Smith D; Daniel F; Ross P J; Oates J; Norman A R
Phase III study of 5FU, etoposide and leucovorin (FELV) compared to epirubicin, cisplatin and 5FU (ECF) in previously untreated patients with advanced biliary cancer.
British journal of cancer 2005;92(9):1650-4.
2005: Starling Naureen; Cunningham David
Second-line therapy for advanced colorectal carcinoma.
Current oncology reports 2005;7(3):173-80.
2005: Ng M; Waters J; Cunningham D; Chau I; Horwich A; Hill M; Norman A R; Wotherspoon A; Catovsky D
Gemcitabine, cisplatin and methylprednisolone (GEM-P) is an effective salvage regimen in patients with relapsed and refractory lymphoma.
British journal of cancer 2005;92(8):1352-7.
2005: Chau I; Norman A R; Cunningham D; Tait D; Ross P J; Iveson T; Hill M; Hickish T; Lofts F; Jodrell D; Webb A; Oates J R
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2005;16(4):549-57.
2004: Katopodis Ourania; Ross Paul; Norman Andrew R; Oates Jacqui; Cunningham David
Sixty-day all-cause mortality rates in patients treated for gastrointestinal cancers, in randomised trials, at the Royal Marsden Hospital.
European journal of cancer (Oxford, England : 1990) 2004;40(15):2230-6.
2004: Chau I; Norman A R; Cunningham D; Waters J S; Topham C; Middleton G; Hill M; Ross P J; Katopodis R; Stewart G; Oates J R
Elderly patients with fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer derive similar benefit without excessive toxicity when treated with irinotecan monotherapy.
British journal of cancer 2004;91(8):1453-8.
2004: Haque Sadaf; Noble Jillian; Wotherspoon Andrew; Woodhouse Christopher; Cunningham David
MALT lymphoma of the foreskin.
Leukemia & lymphoma 2004;45(8):1699-701.
2004: Lal Rohit; Dickson James; Cunningham David; Chau Ian; Norman Andrew R; Ross Paul J; Topham Clare; Middleton Gary; Hill Mark; Oates Jacqui
A randomized trial comparing defined-duration with continuous irinotecan until disease progression in fluoropyrimidine and thymidylate synthase inhibitor-resistant advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(15):3023-31.
2004: Yung L; Cunningham D; Hancock B; Smith P; Maclennan K; Linch D; McMillan A
Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
British journal of cancer 2004;91(4):695-8.
2004: Rao S; Cunningham D; Price T; Hill M E; Ross P J; Tebbutt N; Norman A R; Oates J; Shellito P
Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer.
British journal of cancer 2004;91(5):839-43.
2004: Negri Francesca; Musolino Antonino; Cunningham David; Pastorino Ugo; Ladas George; Norman Andrew R
Retrospective study of resection of pulmonary metastases in patients with advanced colorectal cancer: the development of a preoperative chemotherapy strategy.
Clinical colorectal cancer 2004;4(2):101-6.
2004: Mitry E; Douillard J-Y; Van Cutsem E; Cunningham D; Magherini E; Mery-Mignard D; Awad L; Rougier P
Predictive factors of survival in patients with advanced colorectal cancer: an individual data analysis of 602 patients included in irinotecan phase III trials.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(7):1013-7.
2004: Starling Naureen; Cunningham David
Monoclonal antibodies against vascular endothelial growth factor and epidermal growth factor receptor in advanced colorectal cancers: present and future directions.
Current opinion in oncology 2004;16(4):385-90.
2004: Chau Ian; Norman Andy R; Cunningham David; Waters Justin S; Oates Jacqui; Ross Paul J
Multivariate prognostic factor analysis in locally advanced and metastatic esophago-gastric cancer--pooled analysis from three multicenter, randomized, controlled trials using individual patient data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(12):2395-403.
2004: Chau Ian; Allen Mark J; Cunningham David; Norman Andrew R; Brown Gina; Ford Hugo E R; Tebbutt Niall; Tait Diana; Hill Mark; Ross Paul J; Oates Jacqui
The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(8):1420-9.
2004: Dickson James L B; Cunningham David
Systemic treatment of gastric cancer.
European journal of gastroenterology & hepatology 2004;16(3):255-63.
2004: Price Timothy J; Ross Paul J; Hickish Tamas; Tait Diana; Norman Andy R; Ford Hugo E R; Middleton Gary; Sumpter Kate; Hill Mark; Oates Jacqui; Cunningham David
Phase III study of mitomycin-C with protracted venous infusion or circadian-timed infusion of 5-fluorouracil in advanced colorectal carcinoma.
Clinical colorectal cancer 2004;3(4):235-42.
2004: Maisey N; Norman A; Prior Y; Cunningham D
Chemotherapy for primary gastric lymphoma: does in-patient observation prevent complications?
Clinical oncology (Royal College of Radiologists (Great Britain)) 2004;16(1):48-52.
2004: Assersohn L; Brown G; Cunningham D; Ward C; Oates J; Waters J S; Hill M E; Norman A R
Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15(1):64-9.
2004: Chong G; Cunningham D
Oesophageal cancer: preoperative chemotherapy.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2004;15 Suppl 4():iv87-91.
2003: Yeoh Cheng; Chau Ian; Cunningham David; Norman Andy R; Hill Mark; Ross Paul J
Impact of 5-fluorouracil rechallenge on subsequent response and survival in advanced colorectal cancer: pooled analysis from three consecutive randomized controlled trials.
Clinical colorectal cancer 2003;3(2):102-7.
2003: Sumpter K; Harper-Wynne C; Cunningham D; Gillbanks A; Norman A R; Hill M
Oxaliplatin and capecitabine chemotherapy for advanced colorectal cancer: a single institution's experience.
Clinical oncology (Royal College of Radiologists (Great Britain)) 2003;15(5):221-6.
2003: Mackay H J; Hill M; Twelves C; Glasspool R; Price T; Campbell S; Massey A; Macham M A; Uzzel M; Bailey S M; Martin C; Cunningham D
A phase I/II study of oral uracil/tegafur (UFT), leucovorin and irinotecan in patients with advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(8):1264-9.
2003: Chau I; Jones R; Cunningham D; Wotherspoon A; Maisey N; Norman A R; Jain P; Bishop L; Horwich A; Catovsky D
Outcome of follicular lymphoma grade 3: is anthracycline necessary as front-line therapy?
British journal of cancer 2003;89(1):36-42.
2003: Saini A; Norman A R; Cunningham D; Chau I; Hill M; Tait D; Hickish T; Iveson T; Lofts F; Jodrell D; Ross P J; Oates J
Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer.
British journal of cancer 2003;88(12):1859-65.
2003: Chau Ian; Chan Samuel; Cunningham David
Overview of preoperative and postoperative therapy for colorectal cancer: the European and United States perspectives.
Clinical colorectal cancer 2003;3(1):19-33.
2003: Tebbutt N C; Norman A R; Cunningham D; Allen M; Chau I; Oates J; Hill M
Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil.
British journal of cancer 2003;88(10):1510-5.
2003: Assersohn L; Norman A R; Cunningham D; Iveson T; Seymour M; Hickish T; Massey A; Prior Y; Hill M E
A randomised study of protracted venous infusion of 5-fluorouracil (5-FU) with or without bolus mitomycin C (MMC) in patients with carcinoma of unknown primary.
European journal of cancer (Oxford, England : 1990) 2003;39(8):1121-8.
2003: Chau I; Allen M; Cunningham D; Tait D; Brown G; Hill M; Sumpter K; Rhodes A; Wotherspoon A; Norman A R; Hill A; Massey A; Prior Y
Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer.
British journal of cancer 2003;88(7):1017-24.
2003: Chau Ian; Harries Mark; Cunningham David; Hill Mark; Ross Paul J; Archer Caroline D; Norman Andrew R; Wotherspoon Andrew; Koh Dow Mu; Gill Kairen; Uzzell Maggie; Prior Yvonne; Catovsky Daniel
Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.
British journal of haematology 2003;120(6):970-7.
2003: Jones Robin L; Cunningham David
Clinical and molecular prognostic factors in patients with metastatic colorectal cancer treated with 5-fluorouracil-based chemotherapy.
Clinical colorectal cancer 2003;2(4):235-8.
2003: Chau Ian; Rigg Anne; Cunningham David
Matrix metalloproteinase inhibitors--an emphasis on gastrointestinal malignancies.
Critical reviews in oncology/hematology 2003;45(2):151-76.
2003: Farrugia David C; Ford Hugo E R; Cunningham David; Danenberg Kathleen D; Danenberg Peter V; Brabender Jan; McVicar A David; Aherne G Wynne; Hardcastle Anthea; McCarthy Keith; Jackman Ann L
Thymidylate synthase expression in advanced colorectal cancer predicts for response to raltitrexed.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(2):792-801.
2003: Chau I; Kelleher M T; Cunningham D; Norman A R; Wotherspoon A; Trott P; Rhys-Evans P; Querci Della Rovere G; Brown G; Allen M; Waters J S; Haque S; Murray T; Bishop L
Rapid access multidisciplinary lymph node diagnostic clinic: analysis of 550 patients.
British journal of cancer 2003;88(3):354-61.
2003: Guppy A E; Tebbutt N C; Norman A; Cunningham D
The role of surveillance CT scans in patients with diffuse large B-cell non-Hodgkin's lymphoma.
Leukemia & lymphoma 2003;44(1):123-5.
2003: Rao S; Cunningham D
Adjuvant therapy for colon cancer in the new millenium.
Scandinavian journal of surgery : SJS : official organ for the Finnish Surgical Society and the Scandinavian Surgical Society 2003;92(1):57-64.
2002: Waters J S; Tait D; Cunningham D; Padhani A R; Hill M E; Falk S; Lofts F; Norman A; Oates J; Hill A
A multicentre phase II trial of primary chemotherapy with cisplatin and protracted venous infusion 5-fluorouracil followed by chemoradiation in patients with carcinoma of the oesophagus.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(11):1763-70.
2002: Chau Ian; Cunningham David
Adjuvant therapy in colon cancer: current status and future directions.
Cancer treatment reviews 2002;28(5):223-36.
2002: Tebbutt N C; Norman A; Cunningham D; Iveson T; Seymour M; Hickish T; Harper P; Maisey N; Mochlinski K; Prior Y; Hill M
A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2002;13(10):1568-75.
2002: Chau Ian; Watkins David; Cunningham David
Gemcitabine and its combinations in the treatment of malignant lymphoma.
Clinical lymphoma 2002;3(2):97-104.
2002: Maisey Nick; Chau Ian; Cunningham David; Norman Andrew; Seymour Matt; Hickish Tamas; Iveson Tim; O'Brien Mary; Tebbutt Niall; Harrington Angela; Hill Mark
Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(14):3130-6.
2002: Maisey N R; Norman A; Watson M; Allen M J; Hill M E; Cunningham D
Baseline quality of life predicts survival in patients with advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(10):1351-7.
2002: Cunningham D; Falk S; Jackson D
Clinical and economic benefits of irinotecan in combination with 5-fluorouracil and folinic acid as first line treatment of metastatic colorectal cancer.
British journal of cancer 2002;86(11):1677-83.
2002: Tebbutt N C; Cattell E; Midgley R; Cunningham D; Kerr D
Systemic treatment of colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2002;38(7):1000-15.
2002: Ross P; Nicolson M; Cunningham D; Valle J; Seymour M; Harper P; Price T; Anderson H; Iveson T; Hickish T; Lofts F; Norman A
Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):1996-2004.
2002: Ford Hugo E R; Mitchell Fraser; Cunningham David; Farrugia David C; Hill Mark E; Rees Charlotte; Calvert A Hilary; Judson Ian R; Jackman Ann L
Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(1):103-9.
2002: Chau Ian; Cunningham David
Chemotherapy in colorectal cancer: new options and new challenges.
British medical bulletin 2002;64():159-80.
2001: Chau I; Webb A; Cunningham D; Hill M; Rao S; Ageli S; Norman A; Gill K; Howard A; Catovsky D
An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma.
British journal of haematology 2001;115(4):786-92.
2001: Chau I; Webb A; Cunningham D; Hill M; Waters J S; Norman A; Massey A
Oxaliplatin and protracted venous infusion of 5-fluorouracil in patients with advanced or relapsed 5-fluorouracil pretreated colorectal cancer.
British journal of cancer 2001;85(9):1258-64.
2001: Cunningham D; Coleman R
New options for outpatient chemotherapy--the role of oral fluoropyrimidines.
Cancer treatment reviews 2001;27(4):211-20.
2001: Maisey N; Cunningham D
Current therapy and future prospects in lymphoma.
Expert review of anticancer therapy 2001;1(1):29-41.
2001: Mainwaring P N; Cunningham D; Gregory W; Hoskin P; Hancock B; Norton A J; MacLennan K; Smith P; Hudson G V; Linch D
Mitoxantrone is superior to doxorubicin in a multiagent weekly regimen for patients older than 60 with high-grade lymphoma: results of a BNLI randomized trial of PAdriaCEBO versus PMitCEBO.
Blood 2001;97(10):2991-7.
2001: Cunningham D; James R D
Integrating the oral fluoropyrimidines into the management of advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 2001;37(7):826-34.
2001: Waters J; Cunningham D
The changing face of chemotherapy in colorectal cancer.
British journal of cancer 2001;84(1):1-7.
2000: Sumpter K; Cunningham D
Combination chemotherapy and colorectal cancer.
Seminars in oncology 2000;27(5 Suppl 10):105-11.
2000: Gregory R K; Cunningham D; Fisher T A; Rhys-Evans P; Middleton G W; Bishop L; Wotherspoon A; Trott P A; Nash A G
Investigating lymphadenopathy--report on the first 12 months of the lymph node diagnostic clinic at the Royal Marsden Hospital.
Postgraduate medical journal 2000;76(899):566-8.
2000: Ford H E; Cunningham D; Ross P J; Rao S; Aherne G W; Benepal T S; Price T; Massey A; Vernillet L; Gruia G
Phase I study of irinotecan and raltitrexed in patients with advanced gastrointestinal tract adenocarcinoma.
British journal of cancer 2000;83(2):146-52.
2000: Foran J M; Gupta R K; Cunningham D; Popescu R A; Goldstone A H; Sweetenham J W; Pettengell R; Johnson P W; Bessell E; Hancock B; Summers K; Hughes J; Rohatiner A Z; Lister T A
A UK multicentre phase II study of rituximab (chimaeric anti-CD20 monoclonal antibody) in patients with follicular lymphoma, with PCR monitoring of molecular response.
British journal of haematology 2000;109(1):81-8.
2000: Douillard J Y; Cunningham D; Roth A D; Navarro M; James R D; Karasek P; Jandik P; Iveson T; Carmichael J; Alakl M; Gruia G; Awad L; Rougier P
Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial.
Lancet 2000;355(9209):1041-7.
2000: Maisey N R; Hill M E; Webb A; Cunningham D; Flux G D; Padhani A; Ott R J; Norman A; Bishop L
Are 18fluorodeoxyglucose positron emission tomography and magnetic resonance imaging useful in the prediction of relapse in lymphoma residual masses?
European journal of cancer (Oxford, England : 1990) 2000;36(2):200-6.
2000: Foran J M; Rohatiner A Z; Cunningham D; Popescu R A; Solal-Celigny P; Ghielmini M; Coiffier B; Johnson P W; Gisselbrecht C; Reyes F; Radford J A; Bessell E M; Souleau B; Benzohra A; Lister T A
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2000;18(2):317-24.
2000: Foran J M; Cunningham D; Coiffier B; Solal-Celigny P; Reyes F; Ghielmini M; Johnson P W; Gisselbrecht C; Bradburn M; Matthews J; Lister T A
Treatment of mantle-cell lymphoma with Rituximab (chimeric monoclonal anti-CD20 antibody): analysis of factors associated with response.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2000;11 Suppl 1():117-21.
1999: Popescu R A; Norman A; Ross P J; Parikh B; Cunningham D
Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1999;17(8):2412-8.
1999: Popescu R A; Wotherspoon A C; Cunningham D; Norman A; Prendiville J; Hill M E
Surgery plus chemotherapy or chemotherapy alone for primary intermediate- and high-grade gastric non-Hodgkin's lymphoma: the Royal Marsden Hospital experience.
European journal of cancer (Oxford, England : 1990) 1999;35(6):928-34.
1999: Ross P J; Cunningham D
The management of colorectal cancer: chemotherapy.
Critical reviews in oncology/hematology 1999;30(3):215-26.
1999: Waters J S; Norman A; Cunningham D; Scarffe J H; Webb A; Harper P; Joffe J K; Mackean M; Mansi J; Leahy M; Hill A; Oates J; Rao S; Nicolson M; Hickish T
Long-term survival after epirubicin, cisplatin and fluorouracil for gastric cancer: results of a randomized trial.
British journal of cancer 1999;80(1-2):269-72.
1999: Assersohn L; Norman A; Cunningham D; Benepal T; Ross P J; Oates J
Influence of metastatic site as an additional predictor for response and outcome in advanced colorectal carcinoma.
British journal of cancer 1999;79(11-12):1800-5.
1999: Cunningham D
Setting a new standard--irinotecan (Campto) in the second-line therapy of colorectal cancer: final results of two phase III studies and implications for clinical practice.
Seminars in oncology 1999;26(1 Suppl 5):1-5.
1998: Cunningham D; Pyrhönen S; James R D; Punt C J; Hickish T F; Heikkila R; Johannesen T B; Starkhammar H; Topham C A; Awad L; Jacques C; Herait P
Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer.
Lancet 1998;352(9138):1413-8.
1998: Crawley C; Ross P; Norman A; Hill A; Cunningham D
The Royal Marsden experience of a small bowel adenocarcinoma treated with protracted venous infusion 5-fluorouracil.
British journal of cancer 1998;78(4):508-10.
1998: Popescu R A; Wotherspoon A C; Cunningham D
High-dose chemotherapy and autologous transplantation in lymphomatous polyposis in second remission: three case reports and literature review.
Bone marrow transplantation 1998;22(1):103-6.
1998: Farrugia D C; Norman A R; Cunningham D
Single agent infusional 5-fluorouracil is not effective second-line therapy after raltitrexed (Tomudex) in advanced colorectal cancer.
European journal of cancer (Oxford, England : 1990) 1998;34(7):987-91.
1998: Andreyev H J; Norman A R; Cunningham D; Oates J R; Clarke P A
Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study.
Journal of the National Cancer Institute 1998;90(9):675-84.
1998: Popescu R A; Wotherspoon A C; Cunningham D
Local recurrence of a primary pancreatic lymphoma 18 years after complete remission.
Hematological oncology 1998;16(1):29-32.
1998: Andreyev H J; Norman A R; Oates J; Cunningham D
Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies?
European journal of cancer (Oxford, England : 1990) 1998;34(4):503-9.
1998: Cunningham D
Mature results from three large controlled studies with raltitrexed ('Tomudex').
British journal of cancer 1998;77 Suppl 2():15-21.
1997: Ross P; Norman A; Cunningham D; Webb A; Iveson T; Padhani A; Prendiville J; Watson M; Massey A; Popescu R; Oates J
A prospective randomised trial of protracted venous infusion 5-fluorouracil with or without mitomycin C in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(10):995-1001.
1997: Ross P J; Webb A; Cunningham D; Prendiville J; Norman A R; Oates J
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: the Royal Marsden Hospital experience.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1997;8(2):111-5.
1997: Cunningham D
Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
Tumori 1997;83(1 Suppl):S70-1.
1997: Webb A; Cunningham D; Scarffe J H; Harper P; Norman A; Joffe J K; Hughes M; Mansi J; Findlay M; Hill A; Oates J; Nicolson M; Hickish T; O'Brien M; Iveson T; Watson M; Underhill C; Wardley A; Meehan M
Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(1):261-7.
1997: Waters J S; Ross P J; Popescu R A; Cunningham D
New approaches to the treatment of gastro-intestinal cancer.
Digestion 1997;58(6):508-19.
1997: Findlay M P; Cunningham D; Morgan G; Clinton S; Hardcastle A; Aherne G W
Lack of correlation between thymidylate synthase levels in primary colorectal tumours and subsequent response to chemotherapy.
British journal of cancer 1997;75(6):903-9.
1996: Farrugia D C; Norman A R; Nicolson M C; Gore M; Bolodeoku E O; Webb A; Cunningham D
Unknown primary carcinoma: randomised studies are needed to identify optimal treatments and their benefits.
European journal of cancer (Oxford, England : 1990) 1996;32A(13):2256-61.
1996: Cunningham D; Zalcberg J R; Rath U; Oliver I; van Cutsem E; Svensson C; Seitz J F; Harper P; Kerr D; Perez-Manga G
Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(9):961-5.
1996: Gossios K; Tsianos E V; Nicolson V; Bamias A; Cunningham D; Husband J
CT evaluation of the resectability of gastric cancer postchemotherapy.
Abdominal imaging 1996;21(4):293-8.
1996: Bamias A; Hill M E; Cunningham D; Norman A R; Ahmed F Y; Webb A; Watson M; Hill A S; Nicolson M C; O'Brien M E; Evans T C; Nicolson V
Epirubicin, cisplatin, and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma: response, toxicity, quality of life, and survival.
Cancer 1996;77(10):1978-85.
1996: O'Brien M E; Milan S; Cunningham D; Jones A L; Nicolson M; Selby P; Hickish T; Hill M; Gore M E; Viner C
High-dose chemotherapy and autologous bone marrow transplant in relapsed Hodgkin's disease--a pragmatic prognostic index.
British journal of cancer 1996;73(10):1272-7.
1996: Findlay M; Young H; Cunningham D; Iveson A; Cronin B; Hickish T; Pratt B; Husband J; Flower M; Ott R
Noninvasive monitoring of tumor metabolism using fluorodeoxyglucose and positron emission tomography in colorectal cancer liver metastases: correlation with tumor response to fluorouracil.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(3):700-8.
1996: Cunningham D; Zalcberg J; Smith I; Gore M; Pazdur R; Burris H; Meropol N J; Kennealey G; Seymour L
'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(2):179-82.
1996: Findlay M P; Raynaud F; Cunningham D; Iveson A; Collins D J; Leach M O
Measurement of plasma 5-fluorouracil by high-performance liquid chromatography with comparison of results to tissue drug levels observed using in vivo 19F magnetic resonance spectroscopy in patients on a protracted venous infusion with or without interferon-alpha.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1996;7(1):47-53.
1996: Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
The prognostic value of serum and immunohistochemical tumour markers in advanced gastric cancer.
European journal of cancer (Oxford, England : 1990) 1996;32A(1):63-8.
1996: Ross P J; Webb A; Cunningham D; Prendiville J; Norman A R; Oates J
Infusional 5-fluorouracil in the treatment of gastrointestinal cancers: The Royal Marsden Hospital experience.
The Journal of infusional chemotherapy 1996;6(3):141-4.
1996: Ross P; Heron J; Cunningham D
Cost of treating advanced colorectal cancer: a retrospective comparison of treatment regimens.
European journal of cancer (Oxford, England : 1990) 1996;32A Suppl 5():S13-7.
1995: Andreyev H J; Norman A R; Cunningham D; Padhani A R; Hill A S; Ross P J; Webb A
Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF).
European journal of cancer (Oxford, England : 1990) 1995;31A(13-14):2209-14.
1995: Cunningham D; Zalcberg J R; Rath U; Olver I; Van Cutsem E; Svensson C; Seitz J F; Harper P; Kerr D; Perez-Manga G
'Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The 'Tomudex' Colorectal Cancer Study Group.
European journal of cancer (Oxford, England : 1990) 1995;31A(12):1945-54.
1995: Nicolson M; Webb A; Cunningham D; Norman A; O'Brien M; Hill A; Hickish T
Cisplatin and protracted venous infusion 5-fluorouracil (CF)--good symptom relief with low toxicity in advanced pancreatic carcinoma.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(8):801-4.
1995: Hill M; Norman A; Cunningham D; Findlay M; Watson M; Nicolson V; Webb A; Middleton G; Ahmed F; Hickish T
Impact of protracted venous infusion fluorouracil with or without interferon alfa-2b on tumor response, survival, and quality of life in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(9):2317-23.
1995: Ellis P A; Norman A; Hill A; O'Brien M E; Nicolson M; Hickish T; Cunningham D
Epirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumours.
European journal of cancer (Oxford, England : 1990) 1995;31A(10):1594-8.
1995: Webb A; Scott-Mackie P; Cunningham D; Norman A; Andreyev J; O'Brien M; Bensted J
The prognostic value of CEA, beta HCG, AFP, CA125, CA19-9 and C-erb B-2, beta HCG immunohistochemistry in advanced colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6(6):581-7.
1995: Andreyev H J; Scott-Mackie P; Cunningham D; Nicolson V; Norman A R; Badve S S; Iveson A; Nicolson M C
Phase II study of continuous infusion fluorouracil and interferon alfa-2b in the palliation of malignant neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1486-92.
1995: Hill M; Norman A; Cunningham D; Findlay M; Nicolson V; Hill A; Iveson A; Evans C; Joffe J; Nicolson M
Royal Marsden phase III trial of fluorouracil with or without interferon alfa-2b in advanced colorectal cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(6):1297-302.
1995: Bamias A; Cunningham D; Nicolson V; Norman A; Hill M; Nicolson M; O'Brien M; Webb A; Hill A
Adjuvant chemotherapy for oesophagogastric cancer with epirubicin, cisplatin and infusional 5-fluorouracil (ECF): a Royal Marsden pilot study.
British journal of cancer 1995;71(3):583-6.
1995: Hill M; Milan S; Cunningham D; Mansi J; Smith I; Catovsky D; Gore M; Zulian G; Selby P; Horwich A
Evaluation of the efficacy of the VEEP regimen in adult Hodgkin's disease with assessment of gonadal and cardiac toxicity.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(2):387-95.
1995: Cunningham D; Hill M E; Watson M; Norman A R
Survival after systemic therapy for metastatic colorectal cancer.
Lancet 1995;345(8945):328-9.
1995: Taylor A E; Nicolson V M; Cunningham D
Ovarian metastases from primary gastrointestinal malignancies: the Royal Marsden Hospital experience and implications for adjuvant treatment.
British journal of cancer 1995;71(1):92-6.
1995: Middleton G; Cunningham D
Current options in the management of gastrointestinal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1995;6 Suppl 1():17-25; discussion 25-6.
1995: O'Brien M E; Cunningham D
The role of chemotherapy for metastatic gastric cancer.
The Journal of infusional chemotherapy 1995;5(3):112-6.
1994: Findlay M; Cunningham D; Norman A; Mansi J; Nicolson M; Hickish T; Nicolson V; Nash A; Sacks N; Ford H
A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF).
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(7):609-16.
1994: Hickish T; Robertson D; Clarke P; Hill M; di Stefano F; Clarke C; Cunningham D
Ultrastructural localization of BHRF1: an Epstein-Barr virus gene product which has homology with bcl-2.
Cancer research 1994;54(10):2808-11.
1994: Cunningham D; Paz-Ares L; Gore M E; Malpas J; Hickish T; Nicolson M; Meldrum M; Viner C; Milan S; Selby P J
High-dose melphalan for multiple myeloma: long-term follow-up data.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):764-8.
1994: Cunningham D; Paz-Ares L; Milan S; Powles R; Nicolson M; Hickish T; Selby P; Treleavan J; Viner C; Malpas J
High-dose melphalan and autologous bone marrow transplantation as consolidation in previously untreated myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(4):759-63.
1994: Findlay M; Hill A; Cunningham D; Norman A; Nicolson M; Ford H; Husband J; Evans C; Carter R
Protracted venous infusion 5-fluorouracil and interferon-alpha in advanced and refractory colorectal cancer.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1994;5(3):239-43.
1993: Hill M; Cunningham D; MacVicar D; Roldan A; Husband J; McCready R; Mansi J; Milan S; Hickish T
Role of magnetic resonance imaging in predicting relapse in residual masses after treatment of lymphoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(11):2273-8.
1993: Mansi J L; Cunningham D; Viner C; Ellis E; Meldrum M; Milan S; Gore M
Repeat administration of high dose melphalan in relapsed myeloma.
British journal of cancer 1993;68(5):983-7.
1993: Hickish T; Cunningham D; Colston K; Millar B C; Sandle J; Mackay A G; Soukop M; Sloane J
The effect of 1,25-dihydroxyvitamin D3 on lymphoma cell lines and expression of vitamin D receptor in lymphoma.
British journal of cancer 1993;68(4):668-72.
1993: Hickish T; Roldan A; Cunningham D; Mansi J; Ashley S; Nicolson V; Gore M E; Catovsky D; Smith I E
EPIC: an effective low toxicity regimen for relapsing lymphoma.
British journal of cancer 1993;68(3):599-604.
1993: Findlay M P; Leach M O; Cunningham D; Collins D J; Payne G S; Glaholm J; Mansi J L; McCready V R
The non-invasive monitoring of low dose, infusional 5-fluorouracil and its modulation by interferon-alpha using in vivo 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study.
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 1993;4(7):597-602.
1993: Findlay M; Cunningham D
Current advances in the treatment of gastrointestinal malignancy.
Critical reviews in oncology/hematology 1993;14(2):127-52.
1993: Hickish T; Serafinowski P; Cunningham D; Oza A; Dorland E; Judson I; Millar B C; Lister T A; Roldan A
2'-Chlorodeoxyadenosine: evaluation of a novel predominantly lymphocyte selective agent in lymphoid malignancies.
British journal of cancer 1993;67(1):139-43.
1993: Cunningham D; Findlay M
The chemotherapy of colon cancer can no longer be ignored.
European journal of cancer (Oxford, England : 1990) 1993;29A(15):2077-9.
1992: Mansi J; da Costa F; Viner C; Judson I; Gore M; Cunningham D
High-dose busulfan in patients with myeloma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1992;10(10):1569-73.
1992: Mansi J; Ellis E; Viner C; Mundy J; Smith T; Millar J; Milan S; Gore M; Cunningham D
Gut protection by cyclophosphamide "priming" in patients receiving high-dose melphalan--effect of drug scheduling.
Cancer chemotherapy and pharmacology 1992;30(2):149-51.
1991: Hickish T F; Purvies H; Mansi J; Soukop M; Cunningham D
Molecular monitoring of low grade non-Hodgkin's lymphoma by gene amplification.
British journal of cancer 1991;64(6):1161-3.
1991: Bell J B; Montes A; Gooding R; Riches P; Cunningham D; Millar B C
Comparison of interleukin-6 levels in the bone marrow of multiple myeloma patients with disease severity and clonogenicity in vitro.
Leukemia : official journal of the Leukemia Society of America, Leukemia Research Fund, U.K 1991;5(11):958-61.
1991: Jones A L; Hill A S; Soukop M; Hutcheon A W; Cassidy J; Kaye S B; Sikora K; Carney D N; Cunningham D
Comparison of dexamethasone and ondansetron in the prophylaxis of emesis induced by moderately emetogenic chemotherapy.
Lancet 1991;338(8765):483-7.
1990: Bell J B; Millar B C; Montes-Borinaga A; Joffe J K; Cunningham D; Mansi J; Treleaven J; Viner C; McElwain T J
Decrease in clonogenic tumour cells in bone marrow aspirates from multiple myeloma patients due to the incorporation of cyclophosphamide into treatment with vincristine, adriamycin and methyl prednisolone.
Hematological oncology 1990;8(6):347-53.
1988: Cunningham D; Bradley C J; Forrest G J; Hutcheon A W; Adams L; Sneddon M; Harding M; Kerr D J; Soukop M; Kaye S B
A randomized trial of oral nabilone and prochlorperazine compared to intravenous metoclopramide and dexamethasone in the treatment of nausea and vomiting induced by chemotherapy regimens containing cisplatin or cisplatin analogues.
European journal of cancer & clinical oncology 1988;24(4):685-9.
1987: Cunningham D; Hepplestone A; Gilchrist N L; Dagg J H; Evans I L; Soukop M
Failure of conventional chemotherapy in aggressive lymphomas.
Postgraduate medical journal 1987;63(735):11-5.
1986: Cunningham D; Soukop M; Stuart J F; Setanoians A; Gilchrist N L; Forrest G J; Kaye S B
A clinical and pharmacokinetic phase I study of 1,2,4-triglycidylurazol (TGU, NSC 332488).
European journal of cancer & clinical oncology 1986;22(11):1325-9.
1986: Kerr D J; Kaye S B; Graham J; Cassidy J; Harding M; Setanoians A; McGrath J C; Vezin W R; Cunningham D; Forrest G
Phase I and pharmacokinetic study of LM985 (flavone acetic acid ester).
Cancer research 1986;46(6):3142-6.
1986: Cunningham D; Gilchrist N L; Lee F D; Haxton M; Heppleston A; Forrest G J; Soukop M
T-cell lymphoblastic lymphoma of the uterus complicated by Chlamydia trachomatis pneumonia.
Postgraduate medical journal 1986;62(723):55-7.
1986: Cunningham D; Soukop M; Gilchrist N L; Forrest G J; Carter D C; McArdle C S; Kaye S B; Dobbie J W; Smith M
TNO-6 has no effect in gastrointestinal cancer: N-acetyl-glucosaminidase shows renal damage.
Medical oncology and tumor pharmacotherapy 1986;3(1):25-8.
1986: Cummings J; Forrest G J; Cunningham D; Gilchrist N L; Soukop M
Influence of polysorbate 80 (Tween 80) and etoposide (VP-16-213) on the pharmacokinetics and urinary excretion of adriamycin and its metabolites in cancer patients.
Cancer chemotherapy and pharmacology 1986;17(1):80-4.
1986: Cunningham D; McTaggart L; Soukop M; Cummings J; Forrest G J; Stuart J F
Etoposide: a pharmacokinetic profile including an assessment of bioavailability.
Medical oncology and tumor pharmacotherapy 1986;3(2):95-9.
1985: Cunningham D; Gilchrist N L; Cowan R A; Forrest G J; McArdle C S; Soukop M
Alfacalcidol as a modulator of growth of low grade non-Hodgkin's lymphomas.
British medical journal (Clinical research ed.) 1985;291(6503):1153-5.
1985: Cunningham D; Forrest G J; Soukop M; Gilchrist N L; Calder I T; McArdle C S
Nabilone and prochlorperazine: a useful combination for emesis induced by cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;291(6499):864-5.
1985: Banham S; Dorward A; Hutcheon A; Ahmedzai S; Cunningham D; Burnett A; Soukop M; Lucie N; Kaye S
The role of VP-16 in the treatment of small-cell lung cancer: studies of the West of Scotland Lung Cancer Group.
Seminars in oncology 1985;12(1 Suppl 2):2-6.
1985: Cunningham D; Gilchrist N L; Forrest G J; Soukop M
Onycholysis associated with cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;290(6469):675-6.
1985: Cunningham D; Soukop M; Gilchrist N L; Forrest G J; Hepplestone A; Calder I T; McArdle C S; Hutcheon A W; Kaye S B
Randomised trial of intravenous high dose metoclopramide and intramuscular chlorpromazine in controlling nausea and vomiting induced by cytotoxic drugs.
British medical journal (Clinical research ed.) 1985;290(6468):604-5.
1985: Gilchrist N L; Caldwell J; Watson I D; Cunningham D; Forrest G J; Soukop M; Stewart M; Fitch W
Comparison of serum and cerebrospinal fluid levels of methotrexate in man during high-dose chemotherapy for aggressive non-Hodgkin's lymphoma.
Cancer chemotherapy and pharmacology 1985;15(3):290-4.
1985: Cunningham D; Banham S W; Hutcheon A H; Dorward A; Ahmedzai S; Tansey P; Soukop M; Stevenson R D; Stack B R; Kaye S B
High-dose cyclophosphamide and VP 16 as late dosage intensification therapy for small cell carcinoma of lung.
Cancer chemotherapy and pharmacology 1985;15(3):303-6.
1984: Cunningham D; Soukop M; McArdle C S; Carter D C; Smyth J F; Allan S G; Kaye S B; Sangster G; Calman K C; Hutcheon A W
Advanced gastric cancer: experience in Scotland using 5-fluorouracil, adriamycin and mitomycin-C.
The British journal of surgery 1984;71(9):673-6.
1983: Hutcheon A W; Palmer J B; Soukop M; Cunningham D; McArdle C; Welsh J; Stuart F; Sangster G; Kaye S; Charlton D
A randomised multicentre single blind comparison of a cannabinoid anti-emetic (levonantradol) with chlorpromazine in patients receiving their first cytotoxic chemotherapy.
European journal of cancer & clinical oncology 1983;19(8):1087-90.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

David Cunningham

Research Profile (preview)

Procedures

Chemicals & Drugs

Disorders

Concepts & Ideas

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of David Cunningham (preview)

All Publications